Need help finding what you are looking for?
Contact Us
PUBLISHER: DelveInsight | PRODUCT CODE: 2082689
PUBLISHER: DelveInsight | PRODUCT CODE: 2082689
Diabetic Nephropathy Epidemiology Forecast - 2036
PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Diabetic Nephropathy/ Diabetes Kidney Disease (DKD) Insights and Trends
- According to DelveInsight's analysis, the total prevalent cases of DKD were ~34,000,000 in the 7MM (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
- DKD is more prevalent in the United States due to the high burden of diabetes, rising obesity rates, sedentary lifestyles, and longer disease duration, which collectively increase the risk of chronic kidney complications.
- DKD shows a slight male predominance, with males experiencing a higher disease burden compared to females, primarily due to greater exposure to risk factors such as poor glycemic control, hypertension, and lifestyle-related factors that accelerate kidney damage progression.
- DKD burden is expected to rise over the next decade, driven by increasing diabetes prevalence, aging populations, obesity, and associated comorbidities such as hypertension. Strengthening early screening, optimizing glycemic and blood pressure control, and expanding access to disease-modifying therapies will be critical in shaping future disease trends.
DelveInsight's 'Diabetic Nephropathy/ Diabetes Kidney Disease (DKD) - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the DKD, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan.
Diabetic Nephropathy/ Diabetes Kidney Disease (DKD) Understanding and Diagnosis Algorithm
DKD Overview
Diabetic Kidney Disease (DKD), also known as Diabetic Nephropathy (DN), is a clinical syndrome characterized by persistent albuminuria and a progressive decline in renal function, and the term infers the presence of a typical pattern of glomerular disease. DKD is usually associated with arterial hypertension and increased cardiovascular morbidity and mortality. The causes of DKD are complex and most likely related to many factors, but the major factor is hyperglycemia. In the early stages, there may not be any symptoms. However, as kidney function decreases further, toxic wastes build up. Consequently, patients often feel sick to their stomachs and throw up, lose their appetites, have hiccups, and gain weight due to fluid retention. If left untreated, patients can develop heart failure and fluid in their lungs.
DKD Diagnosis
The detection and diagnosis of DKD can be challenging. Screening and renal biopsy are the two primary diagnostic tests that are conducted to detect DKD in patients. Other diagnoses considered in non-albumin uric DKD are ischemic nephropathy, dysproteinemia, and tubule-interstitial nephritis (TIN). Guidelines from the American Diabetes Association (ADA) and Kidney Disease Improving Global Outcomes (KDIGO) recommend that all people with T2DM should have their renal function and albuminuria measured annually, starting from initial diagnosis in T1DM; this can start from 5 years after diagnosis.
Diabetic Nephropathy/ Diabetes Kidney Disease (DKD) Epidemiology
Key Findings from DKD Epidemiological Analysis and Forecast
- According to DelveInsight's estimates, the total number of prevalent cases of DKD in the 7MM was nearly 34,000,000 cases in 2025 and is projected to increase during the forecasted period.
- The total number of prevalent cases of DKD in the United States was nearly 15,000,000 in 2025.
- In 2025 in the US, approximately 30% of DKD cases are observed in individuals aged 18-59 years, while the majority, around 70%, occur in those aged 60 years and above.
- Among the EU4 and the UK, Germany accounted for the highest number of prevalent cases of DKD, followed by Spain, whereas France accounted for the lowest number of cases in 2025.
- In Japan, approximately 95% of patients in Stages 2-4 actively seek treatment, indicating a high treatment uptake in moderate-to-severe disease stages.
Scope of the Report:
- The report covers a segment of an executive summary, a descriptive overview of DKD, explaining its causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
DKD patient population forecast
Report Key Strengths
- Epidemiology-based (epi-based) Bottom-up Forecasting
- 11-year Forecast
- Patient Burden Trends (by geography)
FAQs:
- What are the disease risks, burdens, and unmet needs of DKD? What will be the growth opportunities across the 7MM concerning the patient population with DKD?
- What is the historical and forecasted DKD patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy:
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders' perspectives on the diagnostic challenges to overcome barriers in the future.
- Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.
Product Code: DIEI0276
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of DKD
4. Epidemiology Forecast Methodology of DKD
5. DKD Epidemiology Overview at a Glance
- 5.1. Patient Share (%) Distribution by Country in 2025 in the 7MM
- 5.2. Patient Share (%) Distribution by Country in 2036 in the 7MM
6. Disease Background and Overview of DKD
- 6.1. Introduction
- 6.2. Types
- 6.3. Signs and Symptoms
- 6.4. Causes
- 6.5. Risk Factors Associated With DKD
- 6.6. Pathophysiology
- 6.7. Diagnosis
- 6.7.1. Differential Diagnosis
- 6.7.2. Diagnosis Algorithm
- 6.7.3. Diagnosis Guidelines
7. Epidemiology and Patient Population of DKD
- 7.1. Key Findings
- 7.2. Assumptions and Rationale
- 7.3. Total Prevalent Cases of DKD in the 7MM
- 7.4. The United States
- 7.4.1. Total Prevalent cases of Diabetic Kidney Disease (DKD) in the US
- 7.4.2. Total Diagnosed Prevalent cases of Diabetic Kidney Disease (DKD) in the US
- 7.4.3. Gender-specific Diagnosed Prevalent Cases of Diabetic Kidney Disease (DKD) in the US
- 7.4.4. Stage-specific Diagnosed Prevalent Cases of Diabetic Kidney Disease (DKD) in the US
- 7.4.5. Age-specific Diagnosed Prevalent Cases of Diabetic Kidney Disease (DKD) in the US
- 7.4.6. Treatment Eligible Cases of Diabetic Kidney Disease (DKD) in the US
- 7.5. EU4 and the UK
- 7.5.1. Total Prevalent cases of Diabetic Kidney Disease (DKD) in the EU4 and the UK
- 7.5.2. Total Diagnosed Prevalent cases of Diabetic Kidney Disease (DKD) in the EU4 and the UK
- 7.5.3. Gender-specific Diagnosed Prevalent Cases of Diabetic Kidney Disease (DKD) in the EU4 and the UK
- 7.5.4. Stage-specific Diagnosed Prevalent Cases of Diabetic Kidney Disease (DKD) in the EU4 and the UK
- 7.5.5. Age-specific Diagnosed Prevalent Cases of Diabetic Kidney Disease (DKD) in the EU4 and the UK
- 7.5.6. Treatment Eligible Cases of Diabetic Kidney Disease (DKD) in the EU4 and the UK
- 7.6. Japan
- 7.6.1. Total Prevalent cases of Diabetic Kidney Disease (DKD) in Japan
- 7.6.2. Total Diagnosed Prevalent cases of Diabetic Kidney Disease (DKD) in Japan
- 7.6.3. Gender-specific Diagnosed Prevalent Cases of Diabetic Kidney Disease (DKD) in Japan
- 7.6.4. Stage-specific Diagnosed Prevalent Cases of Diabetic Kidney Disease (DKD) in Japan
- 7.6.5. Age-specific Diagnosed Prevalent Cases of Diabetic Kidney Disease (DKD) in Japan
- 7.6.6. Treatment Eligible Cases of Diabetic Kidney Disease (DKD) in Japan
8. Appendix
- 8.1. Bibliography
- 8.2. Report Methodology
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
Product Code: DIEI0276
List of Tables
- Table 1: Summary of DKD Epidemiology (2022-2036)
- Table 2: Classification of Diabetic Nephrology
- Table 3: Risk Factors of Diabetic Kidney Disease
- Table 4: Laboratory Evaluation of Diabetic Kidney Disease
- Table 5: Total Prevalent Cases of Diabetes in the 7MM, in thousand (2022-2036)
- Table 6: Total Prevalent Cases of DKD in the 7MM, in thousand (2022-2036)
- Table 7: Diagnosed Prevalent Cases of DKD in the 7MM, in thousand (2022-2036)
- Table 8: Total Prevalent Cases of DKD in the US, in thousand (2022-2036)
- Table 9: Diagnosed Prevalent Cases of DKD in the US, in thousand (2022-2036)
- Table 10: Age-specific Cases of DKD in the US, in thousand (2022-2036)
- Table 11: Stage-specific Cases of DKD in the US, in thousand (2022-2036)
- Table 12: Gender-specific Cases of DKD in the US in thousand (2022-2036)
- Table 13: Treatment Eligible Cases of DKD in the US, in thousand (2022-2036)
- Table 14: Total Prevalent Cases of DKD in EU4 and the UK, in thousand (2022-2036)
- Table 15: Diagnosed Prevalent Cases of DKD in EU4 and the UK, in thousand (2022-2036)
- Table 16: Age-specific Cases of DKD in EU4 and the UK, in thousand (2022-2036)
- Table 17: Stage-specific Cases of DKD in EU4 and the UK, in thousand (2022-2036)
- Table 18: Gender-specific Cases of DKD in in EU4 and the UK in thousand (2022-2036)
- Table 19: Treatment Eligible Cases of DKD in the EU4 and the UK, in thousand (2022-2036)
- Table 20: Total Prevalent Cases of DKD in Japan, in thousand (2022-2036)
- Table 21: Diagnosed Prevalent Cases of DKD in Japan, in thousand (2022-2036)
- Table 22: Age-specific Cases of DKD in Japan, in thousand (2022-2036)
- Table 23: Stage-specific Cases of DKD in Japan, in thousand (2022-2036)
- Table 24: Gender-specific Cases of DKD in Japan in thousand (2022-2036)
- Table 25: Treatment Eligible Cases of DKD in the in Japan, in thousand (2022-2036)
List of Figures
- Figure 1: Diabetic Nephropathy Classification in Japan
- Figure 2: Metabolic Pathway of Diabetic Kidney Disease
- Figure 3: Pathophysiology of Diabetic Kidney Disease
- Figure 4: Barriers to care and opportunities to improve awareness in patients with DKD
- Figure 5: Global Heat Map of Adults With Diabetes
- Figure 6: Total Prevalent Cases of Diabetes in the 7MM (2022-2036)
- Figure 7: Total Prevalent Cases of DKD in the 7MM (2022-2036)
- Figure 8: Diagnosed Prevalent Cases of DKD in the 7MM (2022-2036)
- Figure 9: Total Prevalent Cases of DKD in the US (2022-2036)
- Figure 10: Diagnosed Prevalent Cases of DKD in the US (2022-2036)
- Figure 11: Age-specific Cases of DKD in the US (2022-2036)
- Figure 12: Stage-specific Cases of DKD in the US (2022-2036)
- Figure 13: Gender-specific Cases of DKD in the US (2022-2036)
- Figure 14: Treatment Eligible Cases of DKD in the US (2022-2036)
- Figure 15: Total Prevalent Cases of DKD in EU4 and the UK (2022-2036)
- Figure 16: Diagnosed Prevalent Cases of DKD in EU4 and the UK (2022-2036)
- Figure 17: Age-specific Cases of DKD in EU4 and the UK (2022-2036)
- Figure 18: Stage-specific Cases of DKD in EU4 and the UK (2022-2036)
- Figure 19: Gender -specific Cases of DKD in EU4 and the UK (2022-2036)
- Figure 20: Treatment Eligible Cases of DKD in EU4 and the UK (2022-2036)
- Figure 21: Total Prevalent Cases of DKD in Japan (2022-2036)
- Figure 22: Diagnosed Prevalent Cases of DKD in Japan (2022-2036)
- Figure 23: Age-specific Cases of DKD in Japan (2022-2036)
- Figure 24: Stage-specific Cases of DKD in Japan (2022-2036)
- Figure 25: Gender-specific Cases of DKD in Japan (2022-2036)
- Figure 26: Treatment Eligible Cases of DKD in the in Japan (2022-2036)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.